Atlas Trials

Platinum-Sensitive Primary Peritoneal Carcinoma

2 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Platinum-Sensitive Primary Peritoneal Carcinoma

RecordFirmDate
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer (NCT04034927)National Cancer Institute (NCI)2019-12-04
Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03691376)Roswell Park Cancer Institute2019-03-08

Track Platinum-Sensitive Primary Peritoneal Carcinoma automatically

Every clearance here is in the API, with alerts when new ones post.